Future Growth of Anti-Obesity Drugs Market to Grow at a CAGR of +20.9% During and Forecasts, 2018 To 2025 Forecast Period: Key Vendors like GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd, Nova Nordisk, Pfizer, Rhythm Pharma

Anti-obesity Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2025
Overview: Globally, obesity has nearly tripled since 1975. In 2017, more than 1.9 billion adults, who were 18 years and older were overweight. Of these over 650 million were obese. An obese individual is at a higher risk of developing chronic diseases such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.
The Global Anti-Obesity Drugs Market is estimated to witness a CAGR of 20.9% during the forecast period 2018–2025. The market is analysed based on three segments, namely top FDA approved drugs, types of anti-obesity drugs, and regions.

For Sample Copy of Reports: http://contrivedatuminsights.com/Home/RequestaSample/2444

The Top Key Players include: F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan

Anti-obesity drugs help in reducing body mass either by dipping the hunger or increasing the consumption of calories. The increasing prevalence of obesity globally is a major factor driving the market. It is principally because of wrong eating habits and swiftly varying regime of people. The increasing ingestion of unhealthy food along with the lack of exercises is intensifying the incidence rate of obesity globally.

Basic activities like reducing the intake of unhealthy diet and inculcating workout are not highly effective, and the medical devices like intragastric balloon and bariatric surgery are highly expensive and has high complications. This shows that there is a wide gap for the treatment of obesity. This unmet need is driving the market for anti-obesity drugs market.

Ill effects, such as the risk of mental illness, suicidal symptoms, stroke, are natively impacting the anti-obesity drugs market. Many drugs that were approved previously were withdrawn because of their side effects. Due to these factors’ healthcare specialists have an undesirable insight and do not recommend them to their clients.
Market Analysis: The Global Anti-Obesity Drugs Market is estimated to witness a CAGR of 20.9% during the forecast period 2018–2025. The market is analysed based on three segments, namely top FDA approved drugs, types of anti-obesity drugs, and regions.

Get More Discount: http://contrivedatuminsights.com/Home/GetSpecialPricing/2444

Competitive Analysis: Novo Nordisk, an innovator of drugs in the obesity market, launched Sax Enda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which was first launched for type 2 diabetes as Victoza. Dual therapy for obesity and type 2 diabetes is the latest trend in the market. Therefore, big pharmaceutical companies, such as AstraZeneca, J&J, and Sanofi, are adopting low-risk strategy of using diabetes drugs to treat the obesity related problem. This helps the diabetes market players to enter the obesity market. J&J is intended to enter the market for prescription anti-obesity drugs without further investing in the development of novel molecules.

Benefits: The report provides complete details about the usage and adoption rate of anti-obesity drugs during the forecast period and the various regions. With that, the key stakeholders can know about the major trends, drivers, and investments, along with the details of the commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyse before investing or expanding business in this market.

Table of Content (TOC):
Chapter 1 Introduction and Overview
Chapter 2 Industry Cost Structure and Economic Impact
Chapter 3 Rising Trends and New Technologies with Major key players
Chapter 4 Global Anti-Obesity Drugs Market Analysis, Trends, Growth Factor
Chapter 5 Anti-Obesity Drugs Market Application and Business with Potential Analysis
Chapter 6 Global Anti-Obesity Drugs Market Segment, Type, Application
Chapter 7 Global Anti-Obesity Drugs Market Analysis (by Application, Type, End User)
Chapter 8 Major Key Vendors Analysis of Anti-Obesity Drugs Market
Chapter 9 Development Trend of Analysis
Chapter 10 Conclusion

For More Information: http://contrivedatuminsights.com/Home/InquiryBeforeBuying/2444

Any special requirements about this report, please let us know and we can provide custom report.

About Contrive Datum Insights:
Contrive Datum Insights (CDI) is the most comprehensive database of market-related research. Serious researchers from across the globe seeking up-to-date information on the latest market trends with in-depth analyses turn to Contrive Datum Insights. Our massive database boasts authentic reports published by leading authors and publications. Contrive Datum Insights’ highly motivated and expert in-house team undertakes rigorous screening of the credentials of publishers and authors before accepting their submissions. Such vetting is imperative for internal quality control.

Contact Us:
Alex Jones,
(Sales Manager),
Office : 4859 Slcan Street,
Vancouver,
British Columbia, Canada
+19084598372,
sales@contrivedatuminsights.com
www.contrivedatuminsights.com

This release was published on openPR.